Brokerages Set ABIVAX Société Anonyme (NASDAQ:ABVX) Price Target at $38.67

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have earned an average rating of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $38.67.

Several brokerages have recently weighed in on ABVX. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. JMP Securities restated a “market outperform” rating and set a $33.00 target price on shares of ABIVAX Société Anonyme in a report on Friday, January 10th.

ABIVAX Société Anonyme Price Performance

Shares of ABIVAX Société Anonyme stock opened at $6.09 on Thursday. ABIVAX Société Anonyme has a 12 month low of $5.54 and a 12 month high of $17.02. The stock has a 50 day moving average of $7.57 and a 200 day moving average of $9.96.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ABVX. GAMMA Investing LLC acquired a new position in ABIVAX Société Anonyme in the fourth quarter valued at approximately $29,000. R Squared Ltd purchased a new stake in ABIVAX Société Anonyme in the fourth quarter valued at approximately $36,000. BNP Paribas Financial Markets raised its position in ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the period. Walleye Capital LLC raised its position in ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after purchasing an additional 80,807 shares during the period. Finally, abrdn plc raised its position in ABIVAX Société Anonyme by 34.1% in the fourth quarter. abrdn plc now owns 424,181 shares of the company’s stock valued at $3,105,000 after purchasing an additional 107,750 shares during the period. 47.91% of the stock is currently owned by institutional investors and hedge funds.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.